Preferred Label : Anti-BCMA/PBD ADC MEDI2228;
NCIt synonyms : Anti-BCMA/PBD MEDI2228; Antibody-drug Conjugate MEDI2228; Anti-BCMA ADC MEDI2228; ADC MEDI2228;
NCIt related terms : MEDI-2228;
NCIt definition : An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against
the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that
is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic,
DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential
antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody
moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon
antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic
PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2
positions of guanines on opposite strands of DNA. This induces DNA strand breaks,
inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and
inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for
a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member
13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis
factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found
on the surfaces of plasma cells and is overexpressed on malignant plasma cells.;
UNII : YQ4C0NDW44;
Molecule name : MEDI 2228; MEDI-2228;
NCI Metathesaurus CUI : CL551921;
Origin ID : C150127;
UMLS CUI : C4725626;
Semantic type(s)
- concept_is_in_subset
- has_target
